Neuroplast receives second orphan medicinal product designation for Neuro-Cells®, paving the way for application to both chronic and trauma-induced neurodegenerative diseases

Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product...

Related Keywords

Geleen ,Limburg ,Netherlands ,Amsterdam ,Noord Holland ,Dutch ,Erik Wolters ,Brightlands Agrifood Fund ,Committee For Orphan Medicinal Products ,European Union ,Netherlands Enterprise Agency ,European Medicines Agency ,Dutch Ministry Of Economic Affairs ,Frontotemporal Dementia ,Traumatic Spinal Cord Injury ,Traumatic Brain ,Advanced Therapy Medicinal Product ,Orphan Medicinal Products ,Johannes De Munter ,Lumana Invest ,Brightlands Venture Partners ,Netherlands Enterprise ,Brightlands Chemelot Campus ,Venture Partners ,Chemelot Ventures ,Dutch Ministry ,Economic Affairs ,Spring Lifesciences Communication ,Neuroplast ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,